Recurrence of sarcoidosis after heart or lung transplantation: the importance of long-term follow-up
Website publication date: 14 October 2026.Date of the original paper: 9 October 2026 (online publication)
This section shares educational news and research updates related to sarcoidosis. Evidence can change, so consider the date, source and level of research before drawing conclusions. News items do not provide a diagnosis or a personal treatment plan. Discuss important findings and possible treatment changes with your clinician.
Latest research and professional publications
Here we provide understandable summaries of new research, expert positions and international projects related to sarcoidosis. Each publication highlights what was studied, what the authors concluded, the main limitations of the findings and a link to the source. The information is educational and does not replace a medical examination or a conversation with a doctor.
14 Oct 2026 09:36
Website publication date: 14 October 2026.Date of the original paper: 9 October 2026 (online publication)
14 Oct 2026 09:34
Website publication date: 14 October 2026.Date of the original article: 7 October 2026 (online publication)
14 Oct 2026 09:36
Datum objave na stranici: 14. listopada 2026.Datum izvornog rada: 9. listopada 2026. (online objava)
14 Oct 2026 09:34
Datum objave na stranici: 14. listopada 2026.Datum izvornog rada: 7. listopada 2026. (online objava)
7 Oct 2026 10:28
From immune mechanisms to more precise sarcoidosis diagnosis
7 Oct 2026 10:27
Modern management of sarcoidosis: treatment is increasingly tailored to risk
7 Oct 2026 10:26
Not all patients follow the same path: Swedish study identifies two long-term disease trajectories
7 Oct 2026 10:24
What do clinical trials to date tell us about the treatment of pulmonary sarcoidosis?
7 Oct 2026 10:22
Advanced pulmonary sarcoidosis: the importance of HRCT, lung function and early detection of pulmonary hypertension
5 Oct 2026 20:37
The ERS research network SARCOIDOMICS brings together European centers to improve understanding of sarcoidosis and the risk factors for a more severe disease course. The project promotes coordinated collection of clinical data, imaging findings, and biological samples, as well as connections between researchers from different countries.
5 Oct 2026 20:34
The phase II RESOLVE-Lung trial evaluated namilumab in people with active pulmonary sarcoidosis. The trial included 107 participants. Namilumab did not provide a clinical benefit compared with placebo; a key outcome related to the need for additional treatment occurred in 37.5% of participants in the namilumab group and 23.5% in the placebo group.
5 Oct 2026 20:27
WASOG, with support from AASOG, has published a position paper on a more thoughtful use of oral corticosteroids in sarcoidosis. These medicines can quickly reduce inflammation, but long-term use can cause significant side effects. The authors advocate assessing benefits and risks for each patient and considering steroid-sparing strategies when medically appropriate.
5 Oct 2026 20:22
PREDMETH: in people with pulmonary sarcoidosis, methotrexate achieved a similar effect on lung function to prednisone after 24 weeks. The trial compared two initial treatment options, but this does not mean that either is suitable for everyone.